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2007 she was operated of a left upper lobectomy and lymphadenectomy. The pathology report consistent with metastatic ade-
nocarcinoma of endometrial origin of 4 cm in maximum diameter that do not invades the visceral pleura. The tumor near the
surgical resection margin invades and occludes the bronchial lumen completely. The prevascular lymphadenopathy was free
of tumor involvement. With the diagnosis of lung metastasis of an endometrial adenocarcinoma the patient was sent to our
service for local consolidation therapy. Treatment plan, we administered 30Gy in 6 fractions to the bronchial stump, 5Gy each
session, from 27 September to October 31 of 2007. In each session were performed a bronchoscopy and a dosimetric planning
CT. Tolerance to treatment was excellent. Last control CT was in 3/2012 and informed of a complete response.
Conclusion. After ﬁve year the patient remains disease free. Endobronchial brachytherapy is an effective alternative to achieve
local control after surgery of metastasis.
http://dx.doi.org/10.1016/j.rpor.2013.03.038
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Objective. Review the results of toxicity in patients (p) with prostate cancer treated with permanent brachytherapy with seeds of
I125.
Material and methods. Criteria of incorporation: p with low risk prostate cancer dose 145Gy; intermediate risk, combined Exter-
nal Radiotherapy 45Gy and 110Gy; all had prostate volume <45 cm3 and IPSS minor than 12. The planning system was real
time intraoperatory system SPOT, and SEED-Selectron (Nucletron®). We followed ESTRO guidelines and dose was registered in
neurovascular bundles by D90. IPSS and toxicity has been recorded according to the scale CTC v.4 at diagnosis and the reviews.
Results. 121 patients included (p) in the period of Dic 2008 to Dec 2012. The treatment was exclusive in 95 p (77%) of low risk,
combined in 26p (23%) of intermediate risk. Characteristics: T1c: 99p (82%), T2a 17p (11%), T2c 5p (7%); Gleason 4–5: 2p (2%), 6:
95p (79%), 7: 24p (19%). Medium dose: D90 PTV: 162.2Gy (142.4–188.2); boost: 120.34 (110.3–129.5); D30 urethra md: 112%; D10
urethra med: 119%; D2cc rectum: 89.5%. With median of follow-up: 14.8m, biochemical and local failure (conﬁrmed PET-colina):
1p (0.8%). The toxicity to 12m includes: in the Table 1. G1 G2 G3 Frequency 1 (1.8%) 16 (13.2%) – Nicturia 25 (20.7%) 2 (1.7%) 1 (0.8%)
Incontinency 0 Proctitis 0 1 (0.8%) Impotence 6 (5%) 12 (9.9%). It has not been correlation between the toxicity urinary GII and
D10 uretral, neither impotence GII and D90 in neurovascular bundles: D90 No impotence: 93.8Gy vs D90 G1–2: 98.1Gy (p: ns).
Conclusion. Intraoperatory real time planning reduces late urinary and sexual toxicity. We did not ﬁnd correlation between the
urinary toxicity GII and D10 uretral, neither impotence GII and D90 in neurovascular bundle, although a major follow-up is
necessary.
http://dx.doi.org/10.1016/j.rpor.2013.03.039
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Introduction. Brachytherapy with 125-I seeds in low-intermediate risk prostate carcinoma is a very save treatment, if we respect
the constraint over rectum and urethra as ESTRO recommend Objective Analysis dose to rectum and urethra at our institution
on incorporation of brachytherapy with permanent implants of 125-I seeds in prostate carcinoma with real-time planiﬁcation
and Quick-Link system.
Methods. Between March of 2011 and December of 2012 were performed 41 prostate brachytherapy applications with permanent
implants of 125-I seeds in patients with prostate Adenocarcinoma low-intermediate risk, as monotherapy or combined with
EBRT. Of this patients 87.8% were ≤T2a, 12.2% T2b-c. Mean PSA: 6.73ng/ml (range 4.06–16.7). 87.8% were Gleason≤6 and 7 (3 + 4)
12.2%. Median Prostate volumen was 33 cm3, only one patient had volume 53.8 cm3. System Quick-Link was used with real-time
planiﬁcation, inserting a median of 16 needles and 60 seeds (range 38–82) to cover PTV with 145Gy isodose in radical intent
(92.6%) and 108Gy in combined with EBRT (7.4%) We used Constraints recommended by ESTRO: Uretra D10≤150Gy and during
the progress of learning curve was amended to Uretra D1≤150Gy. Rectum V100≤5%.
Results. Mean V100 in Rectum was 2.9% (between 0.1 and 9.68), 85% of patients with V100≤5% (35/41 patients). Mean D1 in
Uretra was 138Gy (between 121 and 196.8). 88% of patients with D1≤150Gy (36/41 patients). All patients had UrethraD10≤150Gy
following ESTRO recommendations. No patient had complications during the procedure and they all were discharged in the ﬁrst
24h. 1 patient (2.4%) required catheterization for acute urinary retention and there were no cases of acute rectal toxicity.
